Tela Bio (TELA) Stock
Medical device company making hernia and soft tissue implants. Here's the price, business snapshot, and what's worth knowing about Tela Bio in October 2026.
TELA Bio Inc (TELA) develops and commercialises tissue‑guided repair implants for soft‑tissue reconstruction and hernia repair. The company’s products combine biologic and polymer components intended to support healing while reducing complications associated with traditional meshes. As a small‑cap medical devices firm with a market capitalisation around $60m, TELA is in a commercial and clinical growth phase: revenue trends, adoption by surgeons and reimbursement decisions will be key drivers. Investors should consider the typical biotech/medical‑device risks — limited liquidity, quarterly volatility, dependence on regulatory approvals and clinical outcomes, and competition from larger manufacturers. Financials may show uneven revenue while the company invests in sales and evidence generation. This summary is educational only and not investment advice; small‑cap healthcare stocks can be high risk and are suitable only for investors who understand potential for significant gains and losses.
Tela Bio (TELA) Stock Forecast
Analyst price target, next 12 months
$8.15
+614.9% vs today's $1.14
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Tela Bio have a consensus 12-month target of $8.15, above the current price of $1.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 3 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying TELA Bio's stock with a target price of $8.15, indicating strong growth potential.
Financial Health
Tela Bio Inc. is performing well with solid revenue and profit margins, showing positive cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Commercial Traction
Growing product sales and surgeon adoption could drive revenue, though early commercial profiles may be uneven and subject to reimbursement hurdles.
Clinical Evidence
Clinical studies and regulatory milestones can validate technology and expand use, but outcomes and approvals are uncertain and may affect valuation.
Competitive Market
There’s clear demand for improved soft‑tissue repair solutions globally, yet competition from established device makers and pricing pressures remain important risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
